Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
REGN.MX
BUYFLAGRegeneron Pharmaceuticals, Inc. · Healthcare · United States · $64.9B · Avg Vol: $18K/d
78
StockRankGet insider-trade alerts
Q
70
V
55
M
48
P/E (TTM)
15.1x
ROE
14.5%
D/E
0.1x
Dividend %
0.6%
AI CONVICTION THESIS
Regeneron has quality Q69 and value V61, but momentum at M46 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 213.0B | 229.5B | 248.5B | 251.0B | 5.6% | 261.1B | 291.5B | 312.3B | 11.5% |
| EPS (MXN) | 708.88 | 648.34 | 715.71 | 753.68 | 2.1% | 717.34 | — | — | — |
| Shares | 109.6M | 109.4M | 109.6M | 105.7M | -3.5% | 103.0M | — | — | — |
| Debt | 47.3B | 47.3B | 47.3B | 47.4B | 0.1% | 47.4B | — | — | — |
| Equity | 396.6B | 454.5B | 513.7B | 547.0B | 11.3% | — | — | — | — |
| Op CF | 87.8B | 80.4B | 77.4B | 87.1B | -0.2% | 87.7B | — | — | — |
| Inv CF | -66.2B | -55.7B | -43.2B | -11.0B | — | — | — | — | — |
| Fin CF | -17.7B | -31.3B | -38.5B | -65.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+20.6%
SMA 50SMA 200
Close
$725.30
52W High
$815.67
From 52W High
0.9%
SCORE BREAKDOWN
Quality
70
ROIC
14.6%84.8
ROE
14.5%82.2
GP/Assets
16.1%38.9
Op. Margin
20.7%84.2
FCF/Assets
10.1%86.9
Piotroski
550.0
Int. Cover
50.0x88.8
D/E Ratio
0.09x65.1
Current Ratio
3.56x60.0
Value
55
P/E (TTM)
15.1x73.7
EV/EBITDA
14.3x48.1
P/FCF
15.9x68.0
P/B
2.1x58.5
P/S
4.4x45.5
Div Yield
0.6%13.6
Momentum
48
52W High %
89%64.9
RS 6M
-3%46.8
SMA 50/200
0.87x34.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-10%30.4
FUNDAMENTALS
Market Cap
$64.9B
P/E (Forward)
—
Gross Margin
43.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REGN.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REGN.MX | Regeneron Pharmaceuticals, Inc.(you) | $64.9B | 78 | BUY |
| 688235.SS | BeOne Medicines AG | $46.1B | 78 | BUY |
| ARGX | argenx SE | $57.1B | 70 | BUY |
| VRTX | Vertex Pharmaceuticals Incorporated | $121.2B | 76 | BUY |
| UCB.BR | UCB SA | $56.0B | 64 | HOLD |
| RPRX | Royalty Pharma plc | $33.9B | 70 | BUY |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| 0HAV.L | Agilent Technologies, Inc. | $36.7B | 60 | HOLD |
| GMAB.CO | Genmab A/S | $15.9B | 74 | BUY |
| 0J9P.L | Incyte Corporation | $20.6B | 88 | STRONG BUY |
Peer medians: ROE 2.1% · P/E 23.6x · Gross margin 50.3%